Heterogeneity & Subtypes — Global Neurodegeneration Proteomics Consortium (GNPC)
Uncovering the subtypes and shared mechanisms of neurodegenerative disease through the world's largest dementia protein biomarker discovery effort — to sharpen diagnosis and enable target discovery.
The Challenge
Can large-scale proteomic data reveal the subtypes and shared mechanisms that drive neurodegenerative disease?
Our Approach
The world's largest dementia protein biomarker discovery effort.
The lack of treatment and diagnostic options for neurodegenerative disorders remains a major barrier to care for more than 57 million people worldwide. The GNPC unites proteomic and clinical data at unprecedented scale to understand what drives these diseases — both shared and disease-specific — and to inform better diagnosis and treatment.
Launched in 2023, the GNPC is a first-of-its-kind public–private partnership uniting academic, government and industry researchers. It harmonizes proteomic data from dozens of cohorts into a single Harmonized Data Set on AD Workbench.
Each proteomic profile is paired with clinical and diagnostic data, and both longitudinal and cross-sectional data are analyzed to find mechanisms specific to — and shared across — diseases.
Key Research Questions
The consortium's work is organized around a set of priority questions. Each maps to the proteomic and clinical evidence the GNPC is assembling.
Disease Subtypes
Shared & Distinct Mechanisms
Biomarkers & Drug Targets
Aging & Neurodegeneration
Partners & Investigators
The GNPC is a public–private partnership of founding partners, funders and analytics platforms, contributing data across more than twenty international cohorts.
Contributing cohorts
ACE · ALLFTD · ALS TDI · Answer ALS · Banner · BarcelonaBeta · 20+ international groups
Publications & Resources
A full set of GNPC publications can be accessed here: neuroproteome.org/publications